{"id":"didanosine-lamivudine-nevirapine","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Didanosine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that are incorporated into the growing viral DNA chain, causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to and inhibits reverse transcriptase. Together, they provide complementary mechanisms to suppress HIV replication.","oneSentence":"This is a fixed-dose combination of three nucleoside/non-nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:28.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00000902","phase":"PHASE1","title":"A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":217},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00000922","phase":"NA","title":"A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1710},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00197613","phase":"PHASE3","title":"The Adult Antiretroviral Treatment and Resistance Study (Tshepo)","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2002-12","conditions":"AIDS, HIV Infection","enrollment":650},{"nctId":"NCT00013520","phase":"PHASE3","title":"Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1125},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00332306","phase":"PHASE3","title":"Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2006-06","conditions":"Tuberculosis, Human Immunodeficiency Virus Infections","enrollment":180},{"nctId":"NCT00618176","phase":"PHASE4","title":"Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort","status":"COMPLETED","sponsor":"Peking Union Medical College","startDate":"2005-01","conditions":"HIV Infections","enrollment":198},{"nctId":"NCT00002407","phase":"NA","title":"A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"","conditions":"HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Didanosine, Lamivudine, Nevirapine","genericName":"Didanosine, Lamivudine, Nevirapine","companyName":"Tuberculosis Research Centre, India","companyId":"tuberculosis-research-centre-india","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of three nucleoside/non-nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}